Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: A pilot study

Angiology

Volumn 56, Issue 1, 2005, Pages 61-68

  Ghayour Mobarhan, M ^a,b   Lamb, D J ^a,b   Vaidya, N ^a,c   Livingstone, C ^a,c   Wang, T ^a,c   Ferns, G A A ^a,b,c  

^a University of Surrey ^*

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN ANTIBODY; LIPOPROTEIN; PROTEIN ANTIBODY; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LIPOPROTEIN BLOOD LEVEL; MALE; PILOT STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; AUTOANTIBODIES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAT-SHOCK PROTEINS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LONG-TERM CARE; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; STATISTICS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 12944270424     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600108     Document Type: Article

References (41)

1. Lamb DJ, El Sankary W, Ferns GAA: Molecular mimicry in atherosclerosis: A role for heat shock proteins in immunisation. Atherosclerosis 167:177-185, 2003.
2. Mayr M, Metzler B, Kiechl S, et al: Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 99:1560-1566, 1999.
3. Wick G: Atherosclerosis - an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz 25:87-90, 2000.
4. Pockley AG, Georgiades A, Thulin T, et al: Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. Hypertension 42:235-238, 2003.
5. Prummel MF, VanPareren Y, Bakker O, et al: Anti-heat shock protein (hsp)72 antibodies are present in patients with Graves' disease (GD) and in smoking control subjects. Clin Exp Immunol 110:292-295, 1997.
6. Xu QB, Kiechl S, Mayr M, et al: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Clinical significance determined in a follow-up study. Circulation 100:1169-1174, 1999.
7. Hoppichler F, Koch T, Dzien A, et al: Prognostic value of antibody titre to heat-shock protein 65 on cardiovascular events. Cardiology 94:220-223, 2000.
8. Zhu JH, Quyyumi AA, Rott D, et al: Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease. Evidence for an autoimmune component of atherogenesis. Circulation 103:1071-1075, 2001.
9. Kanwar RK, Kanwar JR, Wang DM, et al: Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 21:1991-1997, 2001.
10. George J, Shoenfeld Y, Afek A, et al: Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol 19:505-510, 1999.
11. Afek A, George J, Gilburd B, et al: Immunization of low-density lipoprotein receptor-deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14:115-121, 2000.
12. George J, Greenberg S, Barshack I, et al: Accelerated intimal thickening in carotid arteries of balloon-injured rats after immunization against heat shock protein 70. J Am Coll Cardiol 38:1564-1569, 2001.
13. Pedersen TR, Kjekshus J, Berg K, et al: Randomized trial of cholesterol-lowering in 4,444 patients with coronary-heart-disease - the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
14. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995.
15. Collins R, Armitage J, Parish S, et al: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: A randomised placebo-controlled trial. Lancet 361:2005-2016, 2003.
16. [Anon]: Pleiotropic effects of statins may benefit cardiovascular system. Can J Cardiol 14:777, 1998.
17. Davignon J, Laaksonen R: Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10:543-559, 1999.
18. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22:1452-1458, 2002.
19. Shimizu K, Aikawa M, Takayama K, et al: Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108:2113-2120, 2003.
20. Ferns GAA: Differential effects of statins on serum CRP levels: Implications of recent clinical trials. Atherosclerosis 169:349-351, 2003.
21. Rikitake Y, Kawashima S, Takeshita S, et al: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154:87-96, 2001.
22. Wassmann S, Laufs U, Muller K, et al: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300-305, 2002.
23. Raggatt LJ, Partridge NC: HMG-CoA reductase inhibitors as immunomodulators. Potential use in transplant rejection. Drugs 62:2185-2191, 2002.
24. Weitz-Schmidt G: Lymphocyte function-associated antigen-1 blockade by statins: Molecular basis and biological relevance. Endothelium 10:43-47, 2003.
25. Friedewald WT, Levy RJ, Fredrickson DS: Estimation of low-density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugation. Clin Chim Acta 18:499-502, 1972.
26. Xu Q, Willeit J, Marosi M, et al: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341:255-259, 1993.
27. Ghayour-Mobarhan M, Lamb DJ, Ferns GAA, et al: Antibody titres to heat shock protein 60, 65, and 70 are elevated in dyslipidaemic patients with established CHD (abstract). Atherosclerosis 5:120, 2004.
28. Jialal I, Stein D, Balis D, et al: Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high-sensitivity C-reactive protein levels. Circulation 103:1933-1935, 2001.
29. Mulhaupt F, Matter CM, Kwak BR, et al: Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59:755-766, 2003.
30. Wang TD, Chen WJ, Lin JW, et al: Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: Relations with baseline lipid profiles. Atherosclerosis 170:315-323, 2003.
31. Mulhaupt F, Matter CM, Kwak BR, et al: Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59:755-766, 2003.
32. Homma Y, Homma K, Iizuka S, et al: Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: A twenty-four-week, open-label, dose-increasing study. Curr Ther Res Clin Exp 64:236-247, 2003.
33. Wang X, Tokuda H, Hatakeyama D, et al: Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys 415:6-13, 2003.
34. Sims TJ, Lernmark A, Mancl LA, et al: Serum IgG to heat shock proteins and Porphyromonas gingivalis antigens in diabetic patients with periodontitis. J Clin Periodontol 29:551-562, 2002.
35. Oranje WA, Sels JP, Rondas-Colbers GJ, et al: Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311:91-94, 2001.
36. Nissen SE, Tuzcu EM, Schoenhagen P, et al: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291:1071-1080, 2004.
37. Cannon CP, Braunwald E, McCabe CH, et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504, 2004.
38. Kent SM, Flaherty PJ, Coyle LC, et al: Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 145:e8, 2003.
39. Albert MA, Danielson E, Rifai N, et al: Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. JAMA 286:64-70, 2001.
40. Wan MX, Schramm R, Klintman D, et al: A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon. Br J Pharmacol 140:395-401, 2003.
41. Schett G, Xu QB, Amberger A, et al: Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96:2569-2577, 1995.